Midatech and Immunotope Form Joint Venture, Syntara LLC, for the Development of Immune Therapies
Midatech Group Ltd. and Immunotope Inc announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.
Commenting on the formation of the joint venture, Professor Tom Rademacher, Chairman of Midatech Group said: “We are excited about the formation of Syntara. The joint venture provides a route to nurture the development of new products for the treatment of certain cancers and chronic infections.”
Professor Ramila Philip, President and CSO of Immunotope added: “Syntara will be the first in class of immunotherapy companies with the capabilities of clinically relevant antigen discovery and efficient delivery, which is critical for successful immunotherapy product”.
Under the terms of the agreement, Immunotope and Midatech will both license specific intellectual property to Syntara for the development of immunotherapy products. The joint venture combines Midatech’s expertise and IP in the area of nanomedicine with Immunotope’s experience in immunotherapeutic antigen discovery and validation.
Each company will have equal representation on the Board of Directors that will oversee the management team’s responsibility for Syntara’s product development operations. Syntara will be based in the US with initial capitalisation provided by the parent companies, with the intention to raise additional financing within 6-9 months.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Domainex Secures £1.4m Biomedical Catalyst Award
VASTox prepares to commence next phase of clinical development for two neuro-disorder drug programmes
Elio_García-Austt
OncoMethylome Sciences Changes its Name to MDxHealth
Tom_Smith_(rugby_player)
Rice physicists kill cancer with 'nanobubbles'
Translational_medicine
Algeta demonstrates targeted cancer-killing potential of novel alpha particle linked antibodies - Preclinical studies show 227Th-rituximab more effective at killing CD20-positive lymphoma cells than 90Y-tiuxetan-ibritumomab (Zevalin)
Combating cancer's double whammy - New research to fight life-threatening blood clots in cancer patients

What determines whether breast cancer cells can form metastases? - Reprogrammed clones metastasize less
Livatag follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients
